Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Why this Iranian island looks like Mars after it rains - 2Investigate Business Mastercard Choices for Better Rewards and Rewards
- 3Before trips to Mars, we need better protection from cosmic rays
- 410 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
- 5Toddler given just 3 years to live after strange symptoms makes full recovery
- IDF, police arrest eleven for criminal, terror-related activity over weekend
- Presenting Nintendo's New Pastel Bliss Con Tones for Switch Gamers: 3 Smart Choices
- The most effective method to Guarantee Thorough Inclusion in Senior Protection.
- Nuno Loureiro, MIT physicist, fatally shot at home; police investigate
- Chicago reports first rabies-positive dog in 61 years. What we know.
- Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
- Mali and Canadian miner Barrick agree to resolve tax dispute, ending 2-year standoff
- Why are malnutrition deaths soaring in America?
- A volcanic eruption may have catalyzed the plague's arrival in Europe, study suggests
